60 F
New York
Friday, May 7, 2021

Kazia Therapeutics’ [NASDAQ: KZIA] Paxalisib Receives Orphan Drug Designation

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Kazia Therapeutics [NASDAQ: KZIA] disclosed Monday that its Paxalisib has got the orphan drug designation from the US FDA. Paxalisib is formerly known as GDC-0084 for the treatment of malignant glioma.

Orphan Drug Designation is the special status awarded to the drugs which has the potential to treat rare diseases. The one benefit of ODD is that it provide the Orphan Drug Exclusivity to drug developers.

Another benefit is that it gives opportunities for grant funding, protocol assitance, and finacial benefits includes waiver of New Drug Application fees, and tax credits.

Shares of Kazia Therapeutics soared 2.47% at $7.48 during the trading of Friday. It has day low and high range of $6.86-$7.59, respectively.

In the past 52-weeks of trading, this company’s stocks fluctuated between the low of $2.27 and a high of $9.74. It has moved up 230.11% from its 52-weeks low and moved down -23.20% from its 52-weeks high.

Kazia Therapeutics has a trading volume of 797.73K and an average volume of 566.62K. Looking at its liquidity, its current ratio is 2.40. Similarly, its quick ratio is also 2.40. Furthermore, its market capitalization is 76.07 million.

Kazia disclosed that it will present its data from its ongoing phase II study of paxalisib in glioblastoma at the Society for Neuro-Oncology (SNO) Annual Meeting in November 2020.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...